Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Blackstone Inc. Director's Dealing 2021

Jul 21, 2021

29782_dirs_2021-07-20_95380e04-8e2e-432a-8104-68cadeb74ac2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Imago BioSciences, Inc. (IMGO)
CIK: 0001623715
Period of Report: 2021-07-20

Reporting Person: Clarus Lifesciences III, L.P. (10% Owner)
Reporting Person: Clarus Ventures III GP, L.P. (10% Owner)
Reporting Person: Blackstone Clarus III L.L.C. (10% Owner)
Reporting Person: Blackstone Holdings II L.P. (10% Owner)
Reporting Person: Blackstone Holdings I/II GP L.L.C. (10% Owner)
Reporting Person: Blackstone Group Management L.L.C. (10% Owner)
Reporting Person: SCHWARZMAN STEPHEN A (10% Owner)
Reporting Person: Blackstone Group Inc (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-07-20 Common Stock C 1872217 Acquired 1872217 Indirect
2021-07-20 Common Stock C 1155689 Acquired 3027906 Indirect
2021-07-20 Common Stock C 197131 Acquired 3225037 Indirect
2021-07-20 Common Stock P 150000 $16 Acquired 3375037 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-07-20 Series A convertible Preferred Stock $ C 1872217 Disposed Common Stock (1872217) Indirect
2021-07-20 Series B convertible Preferred Stock $ C 1155689 Disposed Common Stock (1155689) Indirect
2021-07-20 Series C convertible Preferred Stock $ C 197131 Disposed Common Stock (197131) Indirect

Footnotes

F1: Each share of the issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) shares of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on July 20, 2021 and had no expiration date.

F2: Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The general partner of Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Series II preferred stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.

F3: Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.

F4: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.